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Abstract
Glioblastoma (GBM) is the most serious brain tumor and shows a high rate of drug resistance. Wnt signaling is a very important
pathway in GBM that can activate/inhibit other pathways, such as apoptosis and autophagy. In this study, we evaluated the
efficacy of a combination of temozolomide (TMZ) plus curcumin or nanomicellar-curcumin on the inhibition of GBM growth
in vitro, via effects on autophagy, apoptosis, and the Wnt signaling pathway. Two concentrations of curcumin and nanomicellar-
curcumin (i.e., 20 μM and 50 μM) alone, and in combination with TMZ (50 μM) were used to induce cytotoxicity in the U87
GBM cell line. Wnt signaling–, autophagy-, and apoptosis-related genes were assessed by quantitative reverse-transcriptase
polymerase chain reaction (qRT-PCR) andWestern blots. All treatments (except 20 μM curcumin alone) significantly decreased
the viability of U87 cells compared to controls. Curcumin (50 μM), nanomicellar-curcumin alone and in combination with TMZ
significantly decreased the invasion and migration of U87 cells. Autophagy-related proteins (Beclin 1, LC3-I, LC3-II) were
significantly increased. Apoptosis-related proteins (Bcl-2 and caspase 8) were also significantly increased, while Bax protein was
significantly decreased. The expression levels of Wnt pathway–associated genes (β-catenin, cyclin D1, Twist, and ZEB1) were
significantly reduced.
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Introduction
Despite significant developments in therapy during the past
decades, glioblastoma (GBM) remains a life-threatening brain
tumor, with a median survival rate of only 15 months
(Fitzmaurice et al. 2019; Shabaninejad et al. 2020). Standard
therapy comprises a tripartite combination of surgical tumor
resection, radiotherapy, and administration of the adjuvant
DNA-alkylating chemotherapy drug, temozolomide (TMZ).
Despite much research, TMZ remains the most often used
chemotherapeutic agent for GBM (Laws et al. 2003; Yin
et al. 2014).
New chemotherapy protocols, such as concurrent che-
moradiotherapy or loco-regional delivery, have somewhat
improved survival in GBM. Radiotherapy plus TMZ in
combination provides a survival advantage compared to ra-
diotherapy alone, especially in high-grade glioma (Perry
et al. 2010). However, due to the common occurrence of
resistance mechanisms, even the optimum therapy yields
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Curcumin is a naturally occurring phenolic compound
and is the main bioactive component of Curcuma longa
rhizomes, Curcumin has been shown to have many bio-
logical functions, such as antioxidant, anti-inflammatory,
chemopreventive, and anticancer activity (Zhang et al.
2011). In the case of cancer chemotherapy and chemopre-
vention, curcumin has been tested in both phase I and
phase II clinical trials (Dhillon et al. 2008; Strimpakos
and Sharma 2008). This phenolic compound possesses
significant cytotoxic properties as well as the ability to
induce apoptosis in different cancer cells through modu-
lating signaling pathways, apoptotic gene expression, ad-
hesion molecules, growth modulators, and transcription
factors (Duvoix et al. 2005; Shishodia et al. 2007). In
addition to its anticancer activity, its absence of systemic
toxicity and lack of adverse effects have made curcumin
an interesting agent for combination chemotherapy
(Aggarwal et al. 2003). On the other hand, curcumin is
water-insoluble, has unsatisfactory pharmacokinetics,
poor selectivity, and low overall potency. These draw-
backs have meant that the applications of curcumin
in vivo have been rather restricted, reinforcing the impor-
tance of exploring novel curcumin analogs or formula-
tions with a similar safety profile, but improved
pharmaceutic properties (Anand et al. 2007). Previously,
some investigations have reported that curcumin is capa-
ble of potentiating the activity TMZ in GBM, possibly
because curcumin can overcome TMZ resistance in
GBM (Chen et al. 2007; Ramachandran et al. 2012).
TMZ combined with curcumin could target various mo-
lecular and cellular pathways, including autophagy and
the Wnt/catenin signaling pathway. Wnt signaling is a
very important pathway involved in the progression of
various cancers, such as GBM. The Wnt pathway is able
to modulate other cellular pathways such as those respon-
sible for apoptosis and autophagy (Nager et al. 2018;
Qiang et al. 2018).
The present study aimed to evaluate the anticancer effects
of nanomicellar-curcumin in GBM in vitro, with a focus on
the mentioned signaling pathways. We evaluated the efficacy
of combining TMZ with curcumin or nanomicellar-curcumin
on the inhibition of GBM growth via the Wnt signaling, au-
tophagy, and apoptosis pathways.
Materials and Methods
Chemicals and Reagents
Dimethyl sulfoxide (DMSO), TMZ, curcumin, 5-FU, strepto-
mycin, trypsin, penicillin, 4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide (MTT), and matrigel were obtain-
ed from Sigma (St. Louis; MO: USA). Nanomicellar-
curcumin was purchased from Exir NanoSina Company
(Tehran, Iran). The nanomicellar-curcumin used for this study
was obtained from Exir Nano Sina Company (Tehran, Iran).
Each package of nanomicellar-curcumin soft gel included
80 mg of curcumin. “Sina Curcumin” is an extract containing
curcuminoids and is registered in Iran with the IRC number of
1228225765 Master Mix PCR and real-time PCR reagents
were obtained from Amplicon Company (Denmark). Fetal
bovine serum (FBS) and RPMI were from GIBCO
(Germany). Figure 1 illustrates the chemical structures of the
compounds tested.
Antibodies
Specific antibodies against caspase-8 and Bcl2 were pur-
chased from SantaCruz Biotechnology (Santa Cruz; CA:
USA) (Table 1). Specific antibodies against Bax, LC3-II,
Beclin1, LC3-I, and all secondary antibodies came from Cell
Signaling Technology Inc. (Danvers; MA: USA).
Cell Culture
The U87 cell line was obtained from the Pasteur Institute Cell
Bank, Tehran, Iran. Cells were cultured in RPMImediumwith
10% FBS, streptomycin (1% v/v), and penicillin (1% v/v).
Incubation was at 37 °C in 5% CO2. The ethical aspects of
this study were approved by the Institutional Ethics
Committee of Kashan University of Medical Sciences
(IR.KAUMS.REC.1398.028).
Measurement of Cell Viability
The cytotoxicity effects of the drugs and drug combinations
on U87 cells were evaluated by the MTT assay. A cell sus-
pension of 1 × 104 cells/100 μL in RPMI was seeded into a
Fig. 1 Chemical structures of curcumin, nanomicellar-curcumin, and temozolomide
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96-well plate, and incubated for 48 h. After washing with
PBS, the following drugs were added to the wells and incu-
bated for 48 h. Control (no drugs), curcumin 20μM, curcumin
50 μM, nanomicellar-curcumin 20 μM, nanomicellar-
curcumin 50 μM, TMZ 50 μM, curcumin 20 μM+TMZ,
curcumin 50 μM+TMZ, nanomicellar-curcumin 20 μM+
TMZ, and nanomicellar-curcumin 50 μM+TMZ. Then
10 μL of MTT (0.5 mg/mL) was added to the wells and main-
tained at 37 °C for 3–4 h, followed by addition of 100 μL
DMSO and shaking for 15 min. All incubations (single and
combined) were for 48 h. The absorption of the wells was
measured at 570 nm with a plate reader (Organon Teknika;
Netherlands) and the half-maximal inhibitory concentration
(IC50) was measured.
Invasion Assay
Amodified Boyden chamber coated withMatrigel (Biocoat™
Matrigel™ Invasion Chamber; Becton Dickinson GmbH;
Heidelberg: Germany) was used to analyze cell invasion.
The drugs and combinations of drugs as described in
“Measurement of Cell Viability”were added to the upper well
containing 2.5 × 104 U87 cells and 500 μL of serum-free me-
dium for 6 h. Five hundred microliters of medium with 10%
FBS was in the bottom well. The non-invading cells in the
upper chamber were removed with a cotton swab after 6 and
12 h. The cells in the bottom chamber were fixed with 4%
paraformaldehyde for 15 min at room temperature and stained
with 0.5% crystal violet for 10 min. The excess crystal violet
was rinsed away with distilled water. The stained cells were
imaged with an Axioplan-2 microscope (Carl Zeiss Meditec
Incorporation; Jena; Germany) using a Zeiss Plan-
Apochromat 100× objective (Carl Zeiss).
Migration Assay
U87-cells were seeded in a six-well plate at 3 × 105 cells/
well. Cells were cultured to 8% confluency. Then, the drugs
and drug combinations described above were added in
serum-free medium and the cells were incubated for 6 or
12 h. Applying the tip of a yellow pipet, a scratch was made
through the cell monolayer in FBS-free medium. After 6
and 12 h, the cells were imaged with an Axio plan-2
epifluorescence microscope (Carl Zeiss Vision GmbH;
Munchen: Germany) with a Zeiss Plan Apochromat 40×
objective (Carl Zeiss). ImageJ software was used to quanti-
fy the scratch area.
Quantitative Reverse-transcriptase Polymerase Chain
Reaction (qRT-PCR)
1 × 106 U87cells/well in RMPI were seeded in a six-well
plate. The drugs and drug combinations as described above
were added and incubated at 37 °C for 24 h. Total RNA was
extracted by the RNeasyMini-Kit (Qiagen; Hilden: Germany)
based on the manufacturer’s protocol and the RNA content
and purity checked by spectroscopy (NanoDrop 2000,
Germany). A RevertAid First-Strand cDNA Synthesis Kit
Enzyme was used to synthesize cDNA from RNA according
to the manufacturer’s protocol (Fermentas, Maryland, USA).
A quantitative RT-PCR analysis was run using the specific
primers in Table 2 (Macrogene Co., Seoul: Korea), designed
to amplify the β-catenin, ZEB1, cyclin D1, and Twist genes.
Real-time RT-PCRwas run on a LightCycler® 96 system real
Table 1 Sources of different
antibodies employed in the
current study
Antibodies Type Source Catalog no. Company
Bcl-2 Monoclonal Mouse Sc-7382 Santa Cruz Biotech
Bax Polyclonal Rabbit 2772S Cell signaling Technology
Caspase-8 Monoclonal Mouse Sc-56,070 Santa Cruz Biotech
LC3-I Monoclonal Rabbit 2775 Cell signaling Technology
LC3-II Monoclonal Rabbit 2775 Cell signaling Technology
Beclin1 Monoclonal Rabbit 3738 Cell signaling Technology
GAPDH Monoclonal Rabbit 2118S Cell signaling Technology
Table 2 List of primers and their sequences













time thermal cycler (Roche Molecular Systems, USA) using
SYBR Premix Ex Taq (Qiagen, USA). A standard curve of the
cDNA was prepared using the Quantitative PCR Human
Reference RNA (Stratagene; La Jolla: CA) and gene expres-
sion levels were normalized to the level of GAPDH expres-
sion as described (Bava et al. 2005; Chuang et al. 2002).
Relative levels of gene expression were calculated by the




1 × 106 U87cells/well in RMPI were seeded in a six-well
plate. The drugs and drug combinations as described above
were added and incubated at 37 °C for 24 h. Protein concen-
trations in the cell lysate were measured by the BCA method.
Then 20 μg of cell lysates were loaded onto SDS-PAGE and
after electrophoresis were transferred to poly-vinylidene
difluoride membranes (PVDF). The integrated optical densi-
ties of the bands were determined using Image Quant (GE
Healthcare) and the protein bands were visualized by en-
hanced chemiluminescence. All experiments were done in
triplicate.
Statistical Analysis
Gene expression levels were calculated by the Kruskal-Wallis
H test. Correction of the results was conducted using
Benjamini and Hochberg’s false discovery rate. A statistical
software package GraphPad Prism version 6 (CA, USA) and
STATA 14.2 (TX USA) was used to analyze the data. The P
values ≤ 0.05 were considered to be significant.
Results
Combination of Curcumin and TMZ Decreases
Viability of Glioblastoma Cells
The MTT assay was used to assess the cell viability and pro-
liferation of U87 cells. Curcumin 20 μM did not give a sig-
nificant reduction in viability, but all the other groups:
curcumin 50 μM, nanomicellar-curcumin 20 μM and
50 μM, TMZ 50 μM, curcumin 20 μM+TMZ, curcumin
50 μM+TMZ, nanomicellar-curcumin 20 μM+TMZ, and
nanomicellar-curcumin 50 μM+TMZ, showed progressively
significant decreases in viability of U87 cells compared to
controls (P < 0.05; P < 0.05, P < 0.05, P < 0.01, P < 0.01,
P < 0.001, P < 0.001; P < 0.0001) (Fig. 2).
Combination of Curcumin and TMZ Decreases
Glioblastoma Cell Invasion
The invasion capacity of the GBM cells was significantly
decreased following 6 h of incubation with the drugs (except
curcumin 20 μM) as shown in Fig. 3. Curcumin 50 μM (42%
P < 0.05); nanomicellar-curcumin 20 μM (36%, P < 0.05);
nanomicellar-curcumin 50 μM (36%, P < 0.01); TMZ
50 μM (36%, P < 0.01); curcumin 20 μM+TMZ (35%,
P < 0.01); curcumin 50 μM+TMZ (31%, P < 0.01);
nanomicellar-curcumin 20 μM+TMZ (28%, P < 0.001), and
nanomicellar-curcumin 50 μM+TMZ (25%, P < 0.0001). The
decreases in invasion were even more pronounced after 12 h
of incubation. Curcumin 50 μM (30% P < 0.05);
nanomicel la r -curcumin 20 μM (28%, P < 0.05) ;
nanomicellar-curcumin 50 μM (27%, P < 0.05); TMZ
50 μM (24%, P < 0.01); curcumin 20 μM+TMZ (20%,
P < 0.01); curcumin 50 μM+TMZ (18%, P < 0.001);
nanomicellar-curcumin 20 μM+TMZ (16%, P < 0.0001),
and nanomicellar-curcumin 50 μM+TMZ (12%, P < 0.0001).
Combination of Curcumin and TMZ Decreases
Glioblastoma Cell Migration
The migration capacity of the GBM cells as measured by the
scratch wound healing assay and the % of closure was signif-
icantly decreased following 6 h of incubation with the drugs
(except curcumin 20 μM) as shown in Fig. 4. Curcumin
50 μM (42% P < 0.05); nanomicellar-curcumin 20 μM
(35%, P < 0.05); nanomicellar-curcumin 50 μM (35%,
P < 0.05); TMZ 50 μM (34%, P < 0.01); curcumin 20 μM+
Fig. 2 Cell viability. U87 cells were treated with control (no drugs),
C20μM, C50μM, N-C20μm, N-C50μm, TMZ50μM, C20μM+TMZ,
C50μM+TMZ, N-C20μM+TMZ, and N-C50μM+TMZ for 48 h.
Values in bar graphs were expressed as the mean±SEM and the
asterisks show significant differences (P > 0.05, * P ≤ 0.05, ** P ≤ 0.01,
*** P ≤ 0.001, **** P ≤ 0.0001) for the related groups (ANOVA tests).
All experiments were done in triplicate. C: Curcumin; N-C:
Nanomicellar-curcumin
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TMZ (30%, P < 0.01); curcumin 50 μM+TMZ (30%,
P < 0.01); nanomicellar-curcumin 20 μM+TMZ (26%,
P < 0.001), and nanomicellar-curcumin 50 μM+TMZ (24%,
P < 0.0001). The decreases in migration were even more pro-
nounced after 12 h of incubation. Curcumin 50 μM (30%
P < 0.05); nanomicellar-curcumin 20 μM (28%, P < 0.05);
nanomicellar-curcumin 50 μM (27%, P < 0.05); TMZ
50 μM (24%, P < 0.01); curcumin 20 μM+TMZ (20%,
P < 0.01); curcumin 50 μM+TMZ (18%, P < 0.001);
nanomicellar-curcumin 20 μM+TMZ (16%, P < 0.0001),
and nanomicellar-curcumin 50 μM+TMZ (12%, P < 0.0001).
Combination of Curcumin and TMZ Decreases the
Expression of Wnt Signaling Genes in Glioblastoma
Cells
We used GAPDH as a house-keeping gene for the normaliza-
tion of the expression levels of β-catenin, cyclin D1, Twist,
Fig. 3 Cell invasion. U87 cells were treated with control (no drugs),
C20μM, C50μM, N-C20μm, N-C50μm, TMZ50μM, C20μM+TMZ,
C50μM+TMZ, N-C20μM+TMZ, and N-C50μM+TMZ after 6 and
12 h (A, quantification and B, representative images). All experiments
were triplet. Values in bar graphs were expressed as mean±SEM, and the
asterisks show significant differences (P > 0.05, * P ≤ 0.05, ** P ≤ 0.01,
*** P ≤ 0.001, **** P ≤ 0.0001) for the mentioned groups (ANOVA
tests). All experiments were done in triplicate. C: Curcumin; N-C:
Nanomicellar-curcumin
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and ZEB1 genes, employed statistical analysis to detect sig-
nificant differences compared to the non-treated group. The
expression levels of all genes were down-regulated in all treat-
ment groups (except C20μM) in comparison to the controls (P
value < 0.0001). As shown in Table 3 and Fig. 5, the treatment
with the highest effect was N-C50μM+TMZ. The curcumin-
alone groups C20μM, C50μM, N-C20μm, and N-C50μm
had lower efficacy, while the combination treatments
Fig. 4 Cell migration (% closure of the scratch). U87 cells were treated
with control (no drugs), C20μM, C50μM, N-C20μm, N-C50μm,
TMZ50μM, C20μM+TMZ, C50μM+TMZ, N-C20μM+TMZ, and N-
C50μM+TMZ for 6 and 12 h (A, quantification and B, representative
images). Values in bar graphs were expressed as mean±SEM, and the
asterisks show significant differences (P > 0.05, * P ≤ 0.05, ** P ≤ 0.01,
*** P ≤ 0.001, **** P ≤ 0.0001) for the mentioned groups (ANOVA
tests). All experiments were done in triplicate. C: Curcumin; N-C:
Nanomicellar-curcumin
J Mol Neurosci
Fig. 5 Differential expression (fold-change by RT-QPCR) of the genes:
β-catenin, cyclin D1, Twist and ZEB1. U87 cells were treated with
control (no drugs), C20μM, C50μM, N-C20μm, N-C50μm,
TMZ50μM, C20μM+TMZ, C50μM+TMZ, N-C20μM+TMZ, and N-
C50μM+TMZ for 24 h. Values in bar graphs were expressed as mean
±SEM, and the asterisks show significant differences (P > 0.05, * P ≤
0.05, ** P ≤ 0.01, *** P ≤ 0.001) for the mentioned group (ANOVA
tests). All experiments were done in triplicate. C: Curcumin; N-C:
Nanomicellar-curcumin
Table 3 Comparison of expression levels of β-catenin, cyclin D1, Twist and ZEB1 genes as fold change compared to non-treated cells
Genes Non-treatment group Treatment group
1 2 3 4 5 6 7 8 9
F, P F, P F, P F, P F, P F, P F, P F, P F, P F, P
































































Each cell indicated as fold change, P value adjusted through the Benjamini-Hochberg technique for multiple comparisons; NA: not applicable, ns: not
significant. F = fold change, p = P value. 1) C20μM, 2) C50μM, 3) N-C20μm, 4) N-C50μm, 5) TMZ50μM, 6) C20μM+TMZ, 7) C50μM+TMZ 8) N-
C20μM+TMZ, 9) N-C50μM+TMZ. C: Curcumin; N-C: Nanomicellar-curcumin
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(C20μM+TMZ, C50μM+TMZ, N-C20μM+TMZ, N-
C50μM+TMZ) had the largest efficacy.
Combination of Curcumin and TMZ Increases
Expression of Autophagy-related Proteins in
Glioblastoma Cells
Western blotting analysis showed that all the treatments (ex-
cept C20μM) could increase the expression of all three
autophagy-related proteins (LC3-I, LC3-II, Beclin1) (Fig. 6).
The combination N-C50μM+TMZ had the largest effect with
the expression levels of all three proteins being approximately
doubled.
Combination of Curcumin and TMZ Modulates the
Levels of Apoptosis-related Proteins in Glioblastoma
Cells
Western blotting analysis showed that all the treatments (ex-
cept C20μM) could significantly modulate the levels of
apoptosis-related proteins (Fig. 7). The pro-apoptotic proteins
(caspase 8 and Bax) were both up-regulated, while the anti-
apoptotic Bcl-2 protein was down-regulated. N-C50μM+
TMZ had the most pronounced effect, producing about dou-
ble the amount of caspase 8 and Bax, and about half the
amount of Bcl2.
Discussion
The current study found that curcumin, nano-micelle
curcumin, and TMZ all used alone-exerted anti-tumor effects
against the U87 cells. When used in combination, the effects
of these drugs were more pronounced. The anti-GBM effects
of these treatments were mediated by the modulation of a
variety of GBM-related pathways, including Wnt signaling,
apoptosis, and autophagy-related genes and proteins. All treat-
ment groups (except C20μM) were able to decrease the ex-
pression levels of Wnt signaling–related genes, including β-
catenin, cyclin D1, Twist, and ZEB1 in U87 cells.
Metastasis of tumor cells contributes to tumor-related mor-
tality. The epithelial–mesenchymal transition (EMT) is an im-
portant mechanism enabling tumor cells of epithelial origin to
alter their phenotype, and thereby to metastasize to distant
locations. The activation ofWnt signaling has been implicated
in the EMT and in tumor invasion in pancreatic, breast, and
bladder tumors (among others) (Sarrio et al. 2012; Smit and
Peeper 2011; Xue et al. 2011). The up-regulation of positive
modulators of Wnt signaling was shown to enhance the ex-
pression of EMT-related genes, including N-cadherin, SLUG,
TWIST, SNAIL, and ZEB1 (Howe et al. 2003; Lee et al.
2016; Scheel et al. 2011; Yang et al. 2010). For instance, both
an increase in GBM cell motility and also the up-regulation of
ZEB1 expression were mediated by ectopic expression of a
constitutively active β-catenin protein (Kahlert et al. 2012).
On the other hand, suppression of β-catenin expression
Fig. 6 Autophagy-related proteins (Beclin 1, LC3-I & LC3-II) by
Western blotting. U87 cells were treated with control (no drugs),
C20μM, C50μM, N-C20μm, N-C50μm, TMZ50μM, C20μM+TMZ,
C50μM+TMZ, N-C20μM+TMZ, and N-C50μM+TMZ for 24 h. (A,
representative images; B, quantification). Values in bar graphs were
expressed as mean±SEM, and the asterisks show significant differences
(P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001) for the mentioned
group (ANOVA tests). All experiments were done in triplicate. C:
Curcumin; N-C: Nanomicellar-curcumin
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inhibited cellular invasion in LN229 and U87MG GBM cells
(Yue et al. 2010).
As mentioned above, TMZ is the drug of choice for the
chemotherapy of GBM. It has been shown that several signal-
ing pathways, including Notch, Wnt/β-catenin, as well as
Sonic Hedgehog are correlated with the development of
TMZ resistance in GBM (Ulasov et al. 2011; Tan et al.
2018). Tomar and colleagues evaluated TMZ-induced chang-
es in diverse signal transduction pathways via surveying the
TMZ-regulated transcriptome in glioma cells (Tomar et al.
2019).Wnt/β-catenin was up-regulated, as well as many other
pathways by using the Gene Set Enrichment Analysis (GSEA)
in TMZ-treated cells. In a time-dependent and concentration-
dependent manner, TMZ was found to increase the TOPflash
luciferase reporter activity (a Wnt-responsive reporter), en-
hance pGSK-3β (S9), and reduce phosphorylated β-catenin
(S33/37/T41) levels, accompanied by an increase in the pro-
tein levels of Wnt targets. TMZ-treated cells showed no
change in levels of Wnt ligands; however, the PI3K inhibitor
(LY294002) blocked the TMZ–induced Wnt/β-catenin acti-
vation and suppressed Akt activation. Additionally, TMZ ac-
tivated the mammalian target of rapamycin (mTOR) and the
Wnt/β-catenin independently of ATM/Chk2 signaling.
Therefore, it was concluded that, in TMZ-treated cells, the
activation of the Wnt/β-catenin pathway was due to an
ATM/Chk2-independent PI3K/Akt/GSK-3 cascade, and addi-
tionally could be a mechanistic explanation for the develop-
ment of chemoresistance to TMZ in glioma (Tomar et al.
2019).
Curcumin has previously been tested both used alone and
as a component of combination therapies for several different
cancer types, including prostate, oral, colorectal, and breast
(Bose et al. 2015). Moreover, curcumin has been reported to
modulate Wnt/β-catenin signaling in lung, ovarian, and blad-
der cancer cells (Shi et al. 2017; Yen et al. 2019). In one study
by Ghasemi and colleagues, the antitumor effects of erlotinib
and nano-micellar curcumin were evaluated in U-373 cells in
a spheroid model and in monolayer cell culture (Hesari et al.
2019). The induction of apoptosis and cell cycle alterations
were characterized in GBM cells. The anti-proliferative activ-
ity of erlotinib and nanomicellar curcumin was also evaluated.
The cell cycle effects,Wnt/β-catenin pathway activity, as well
as nuclear factor κB (NF-κB) expression level were assessed.
It was concluded that nanomicellar curcumin inhibited U-373
cell growth by regulating the NF-κB and Wnt pathways.
Treatment with erlotinib and nanomicellar curcumin produced
an initial G2/M cell cycle arrest, subG1 apoptosis, as well as
the formation of apoptotic bodies. It was proposed that
nanomicellar curcumin affected NF-κB pathway via reducing
the expression of p-65 or by suppressing Wnt/β-catenin sig-
naling by decreasing the expression level of cyclin D1 (Hesari
et al. 2019).
Our findings showed that all the treatment groups (except
C20μM) could increase the expression levels of autophagy-
associated genes, such as Beclin 1, LC3-I, as well as LC3-II in
U87 cells. It is likely that the inhibition of Wnt signaling by
the drugs can trigger the activation of autophagy. Other stud-
ies have reported that a range of therapeutic interventions can
Fig. 7 Apoptosis-related proteins (Bax, Bcl-2 and caspase 8) by Western
blotting. U87 cells were treated with control (no drugs), C20μM,
C50μM, N-C20μm, N-C50μm, TMZ50μM, C20μM+TMZ, C50μM+
TMZ, N-C20μM+TMZ, and N-C50μM+TMZ for 24 h. (A, representa-
tive images; B, quantification). Values in bar graphs were expressed as
mean±SEM, and the asterisks show significant differences (P > 0.05, *
P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001) for the mentioned group (ANOVA
tests). All experiments were done in triplicate. C: Curcumin; N-C:
Nanomicellar-curcumin
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activate autophagy in GBM cells, some via inhibition of Wnt
signaling (Shahcheraghi et al. 2020).
Autophagy is designed to augment the metabolism of nor-
mal cells under starvation conditions, and has attracted much
attention regarding its role in the bioenergetics and progres-
sion of tumors (Kriel and Muller-Nedebock 2018). mTOR-
dependent autophagy is designed to allow the bulk degrada-
tion of damaged or expired cytosolic organelles or proteins,
providing additional essential metabolic substrates for the tri-
carboxylic acid cycle and glycolysis. This suggests that au-
tophagy could be considered as an energy reservoir for
allowing tumor proliferation under starvation or hypoxic con-
ditions (Kimmelman and White 2017). However on the other
hand, autophagy can also play an anti-tumor function as has
been seen in the response to therapy of gliomawith TMZ (Zou
et al. 2014). Given the molecular crosstalk between modula-
tors of autophagy and apoptosis, increased GBM cell death
has been found in recently performed studies using a combi-
nation of either autophagy inhibitors (e.g., bafilomycin or
hydroxychloroquine) or autophagy inducers (e.g.,
temsirilomus or rapamycin) with chemotherapeutic agents
(Arcella et al. 2013; Rangwala et al. 2014).
Curcumin can induce both apoptosis and autophagy in
brain tumor cells or in colon cancer cells (Fu et al. 2018; Li
et al. 2017; Zanotto-Filho et al. 2015; Zhang et al. 2016), and
also in gastric cancer cells (Fu et al. 2018; Li et al. 2017). Lee
et al. investigated the effects of curcumin on autophagy-
induced A172 human GBM cell death (Lee et al. 2019).
Autophagy was induced in a time-dependent manner after
incubation of A172 cells with 10μMcurcumin. The cell death
mediated by curcumin was decreased by addition of the au-
tophagy inhibitors, LY294002, hydroxychloroquine (HCQ),
or 3-methyladenine (3-MA). Cell death was also suppressed
via coincubation with the autophagy inducer, rapamycin.
After incubation of the cells in serum-free medium, the level
of LC3-II was increased, along with an increase in viability,
resulting suppression of curcumin-induced cell death. After
addition of small interfering RNA against Beclin1 or Atg5,
the cell death was attenuated through suppression of
curcumin-mediated autophagy. They concluded that the ef-
fects of curcumin were differentially affected by inducers
and inhibitors of autophagy (Lee et al. 2019). In another study,
Yin and co-workers carried out both in vitro (U87MG cell
line) and in vivo (xenograft mouse model) experiments to
assess the possible interaction between TMZ and curcumin
in GBM anticancer therapy (Yin et al. 2014). Curcumin was
shown to enhance the therapeutic response to TMZ via in-
creasing apoptosis. They also investigated the potential apo-
ptotic pathways. The combination of TMZ and curcumin pro-
duced reactive oxygen species (ROS) explaining the synergis-
tic effects, because ROS could sensitize the cells to TMZ
cytotoxicity. Single therapy with either TMZ or curcumin
could suppress mTOR and phosphorylated AKT, while their
combination led to more pronounced effects. This suggests
that inhibition of AKT/mTOR signaling contributes to the
enhanced apoptosis caused by the combination of TMZ and
curcumin (Yin et al. 2014).
Our work demonstrated that all the treatment groups (ex-
cept C20μM) were able to increase the expression levels of
apoptosis-inducing genes including Bax and caspase 8 (and
decrease anti-apoptotic Bcl2) in U87 cells. It seems that inhi-
bition of Wnt signaling has a central role in the activation of
apoptosis. Previous studies indicated that some therapeutic
approaches can inhibit Wnt signaling and activate apoptosis
in GBM cells (Qiang et al. 2018).
Apoptosis is a conserved strategy to maintain homeostasis,
while it is also a consensus mechanism of many anticancer
drugs (Jaattela 2004). This process is mediated either via spe-
cific cell surface receptors or via a mitochondrial process both
of which activate proteolytic enzymes (Ashkenazi and Dixit
1998; Green and Reed 1998). The initiation and promotion of
apoptosis are regulated by caspases, which are a family of
cysteine proteases (Earnshaw 1999). In receptor-mediated ap-
optosis, caspase-8 directly activates caspase-3 (Stennicke
et al. 1998). Caspase-8 can also cleave the Bid protein to
produce a truncated Bid (tBid). tBid then interacts with the
pro-apoptotic Bax resulting in the release of cytochrome c
from the mitochondria and its translocation to the cytoplasm
(Desagher et al. 1999).
Curcumin is an activator of the mitochondrial caspase path-
way to promote apoptosis. Curcumin has been shown to inac-
tivate Akt, and also inhibit IAP, Bcl-xL, and Bcl-2. It also
leads to the mitochondrial release of cytochrome c to activate
caspase-3 for apoptosis in Caki cells (Woo et al. 2003).
Curcumin blocked IAP and Bcl-xL leading to cytochrome c
release and activation of caspase-3 in U937 cells (Bae et al.
2003). In HL-60 cells, curcumin led to cytochrome c release,
caspase-8-mediated Bid cleavage, as well as caspase-3 activa-
tion (Anto et al. 2002). In Jurkat cells, curcumin led to
caspase-3-independent apoptosis. Curcumin induced apopto-
sis and inhibited proliferation in human pancreatic cancer cells
by down-regulation of nuclear factor kappa B (NF-κB)
(Duvoix et al. 2005; Li et al. 2004). Karmakar et al. studied
curcumin-mediated apoptosis in T98G cells (Karmakar et al.
2006). Using trypan blue dye, they showed a curcumin dose-
dependent reduction in cell viability. ApopTag and Wright
staining showed an apoptotic morphology after 24 h exposure
to 25 μM and 50 μM curcumin. Western blotting showed
caspase-8 activation and Bid cleavage to tBid. The involve-
ment of the mitochondrial-mediated has been shown by an
increased Bax:Bcl-2 ratio, mitochondrial release of cyto-
chrome c, activation of the second mitochondrial activator of
caspases (Smac), direct IAP binding protein with low pI
(DIABLO), and apoptosis-inducing-factor (AIF). Down-
regulation of NF-κB, over-expression of the inhibitor of nu-
clear factor-kappa B alpha (I-κBα), and down-regulation of
J Mol Neurosci
inhibitor-of-apoptosis proteins (IAPs, such as c-IAP1 and c-
IAP2) in T98G cells, together showed suppression of cell
survival signaling. Caspase-9 was activated to a 35-kD frag-
ment and caspase-3 to a 20-kD fragment. Both caspase-3 and
calpain could cleave the 270-kD alpha-spectrin at specific
sites to produce two spectrin breakdown products (SBDP) of
120 kD and 145 kD. Taken together, this data showed that
curcumin could mediate both receptor-mediated and
mitochondria-mediated proteolytic cascades to trigger apopto-
sis in T98G cells (Karmakar et al. 2006).
The findings of the present study showed that curcumin
(expect C20μM), nanomicellar-curcumin alone, and in com-
bination with TMZ could induce apoptosis, autophagy, and
inhibit the EMT process in GBM cells. We suggest that a
combination of nanomicellar-curcumin plus TMZ might be
tested as a new clinical strategy to treat recurrent GBM post-
surgery.
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